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a  b  s  t r  a  c  t
Worldwide  growth  and  performance-enhancing  substances  are  used  in cattle  husbandry  to  increase
productivity.  In certain  countries  however  e.g., in  the  EU,  these  practices  are  forbidden  to  prevent  the
consumers  from  potential  health  risks  of  substance  residues  in food.  To  maximize  economic  proﬁt,  ‘black
sheep‘  among  farmers  might  circumvent  the detection  methods  used  in  routine  controls,  which  high-
lights  the  need  for an  innovative  and  reliable  detection  method.  Transcriptomics  is a promising  new
approach  in  the  discovery  of  veterinary  medicine  biomarkers  and also  a missing  puzzle  piece,  as  up  to
date,  metabolomics  and  proteomics  are  paramount.  Due  to increased  stability  and  easy  sampling,  cir-
culating  extracellular  small  RNAs  (smexRNAs)  in bovine  plasma  were  small  RNA-sequenced  and  their
potential  to serve  as biomarker  candidates  was  evaluated  using  multivariate  data  analysis  tools.
After  running  the  data  evaluation  pipeline,  the proportion  of  miRNAs  (microRNAs)  and  piRNAs  (PIWI-
interacting  small  non-coding  RNAs)  on the  total  sequenced  reads  was  calculated.  Additionally,  top  10
signatures  were  compared  which  revealed  that  the  readcount  data  sets  were  highly affected  by  the  most
abundant  miRNA  and  piRNA  proﬁles.  To  evaluate  the  discriminative  power  of  multivariate  data  analyses
to  identify  animals  after  veterinary  drug  application  on  the basis  of smexRNAs,  OPLS-DA  was  performed.
In  summary,  the quality  of miRNA  models  using  all mapped  reads  for both  treatment  groups  (animals
treated  with steroid  hormones  or the -agonist  clenbuterol)  is  predominant  to  those  generated  with
combined  data  sets  or piRNAs  alone.  Using  multivariate  projection  methodologies  like  OPLS-DA  have
proven  the  best potential  to  generate  discriminative  miRNA  models,  supported  by small  RNA-Seq  data.
Based  on the  presented  comparative  OPLS-DA,  miRNAs  are  the  favorable  smexRNA  biomarker  candidates
in the  research  ﬁeld  of veterinary  drug  abuse.
thor©  2015  The  Au
. IntroductionMonitoring of chemical contaminations, species fraud and prod-
ct mislabelings in food is a complex task for control laboratories.
ecent pan-European food safety affairs, for example the horse-
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LS, partial least-squares projection; rpm, reads per million; small RNA-Seq, small
NA-Sequencing; smexRNA, circulating extracellular small RNA.
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meat scandal in 2013, underline the need for sophisticated and
reliable analytical methods as well as sufﬁciently frequent routine
investigations in food producing animals [1]. For ofﬁcial labo-
ratories, the conventional methods for screening for forbidden
veterinary drug compounds are RIA (radio immuno assay) and
ELISA (enzyme-linked immunosorbent assay), and for the conﬁr-
mation, it is mass spectrometry (MS) combined with gas (GC–MS)
or liquid chromatography (LC–MS) [2]. These verifying approaches
persue the direct tracking of targeted chemical compounds and/or
their metabolites in various food, feed or biological samples. As
corresponding analytical protocols are based on the direct detec-
tion of the target substance in a sample matrix, the chemical and
physical properties of this substance must be known in advance.
For example, to test the compliance with regulations in antibi-
otics surveillance, a maximum threshold of antibiotic residues
may  not be exceeded in the detection window. However, in the
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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ase of an illegal abuse, where unknown substances or undeﬁned
rug cocktails with low-dose single compounds were adminis-
ered, chromatographic systems are limited. This is especially the
ase when the substance itself has already been metabolized (but
he physiological effect is still existent), or due to signal to noise
atio in MS  and the unknown mass of the applied drug(s). Next
o chromatographical methods or immunoassays, new and inno-
ative techniques have emerged in veterinary medicine in the
ast years. Since recently, veterinary drug abuse can be detected
y ﬁnding endogenous molecular biomarkers on the transcrip-
omic, proteomic or metabolomic level that indirectly indicate
xogenous physiological modiﬁcations [3]. With the objective of
ontrolling veterinary drug abuse, metabolomics approaches have
o far shown to be effective in detecting growth-promotor abuse in
ovines [4–6], and in racehorses [7,8]. Rapid technological advance-
ents in these “-omics” sciences allow now a comprehensive
igh-throughput screening for differentially expressed biomark-
rs. Thus, according to a physiological condition, disease status, or
rug application, the biomarker signature is capable of revealing
peciﬁc biological traits or a measurable change in the organism
9]. Seen from the genetic point of view, the transcription of genes
s a fast and highly dynamic process that adapts to environmen-
al stimuli, such as medication, making the transcriptome ideally
uitable for the discovery of new biomarkers. The transcriptome
overs inter alia a RNA class called microRNAs (miRNA). These
mall, non-protein coding molecules with a length of typically
8 to 25 nucleotides act as modulators of mRNA targets on the
ost-transcriptional level. By suppressing the mRNA translation or
romoting mRNA destabilization, miRNAs play key roles in reg-
lating gene expression in a multitude of healthy and pathologic
iological processes [10]. The successful identiﬁcation of miRNA
iomarkers is already evident in clinical diagnostics, such as early
isease detection, progression monitoring and prognosis [11]. In
eterinary drug analysis, it was also possible to establish miRNA
upported biomarkers in bovine liver to detect anabolic steroid
reatment [12]. In the year 2008, miRNAs were also detected
s free, extracellular RNA (exRNA) in the bloodstream [13] and
he potential usability of circulating nucleic acids as biomarkers
as promptly recognized and investigated. Since then, circulating
xtracellular small RNAs (smexRNA) have been detected in other
uman body ﬂuids, e.g., milk, saliva, tears, cerebrospinal ﬂuid, urine
tc. [14]. Among these smexRNAs are also a recently very emerg-
ng class of transcriptional molecules, the PIWI-interacting small
on-coding RNAs (piRNAs). They are slightly longer than miRNAs
25 to 32 nucleotides), but also show post-transcriptional regu-
atory functions. Initially detected in the germ line of drosophila,
iRNAs are involved in RNA silencing and therefore in gene expres-
ion regulation (as reviewed in [15]). In biomarker development,
t was already veriﬁed that circulating piRNAs own the potential
o serve as human biomarkers for several cancer types, for exam-
le gastric cancer [16]. Focusing animal sciences, proteomics and
etabolomics are now gradually ﬁnding their way into veterinary
edicine and food safety analyses, but transcriptomics and espe-
ially the analysis of small RNAs and/or smexRNAs have not yet
ully arrived.
Worldwide growth and performance-enhancing substances are
sed in cattle husbandry to increase productivity. Livestock farming
trives to promote faster weight gains, increased feed conversion
fﬁciencies and heavier carcasses to maximize economic proﬁt.
owever, the use of anabolic agents is prohibited in certain coun-
ries, including the European Union (EU) since the EU Council
irective 88/146/EC188 entered into force in 1988. From that year
n, all growth promoting agents including steroid hormones and
-adrenergic agonists have been prohibited from animal breedingand Quantiﬁcation 5 (2015) 15–22
practices across European markets. This ban was  mainly due to pre-
cautionary food safety reasons to prevent consumers from possible
health risks caused by residue carryover [17]. Also the import of
products derived from hormone-treated cattle is legally forbidden
in the EU. Due to ﬁnancial beneﬁts, an abuse by application of illicit
substances is still frequently suspected in meat production [18]. To
circumvent supervisory authorities and positive test results, alter-
native compounds as well as application scenarios have emerged.
Applying transcriptomics in the ﬁeld of food safety constitutes a
new innovative screening strategy for a reliable and effective con-
trol method to maintain legislation. First studies demonstrated that
the monitoring of mRNA expression ratios has already proven to be
a useful tool for biomarker development to trace growth-promotor
abuse [19–21] however, far less is known about the applicability of
smexRNAs in this context.
If the aim is to measure small non-coding RNAs in a high-
throughput approach, small RNA-Sequencing (small RNA-Seq)
is the strategy of choice. This allows the holistic and parallel
sequencing-by-synthesis analysis of the whole transcriptome of
multiplexed samples. To study the inﬂuence of anabolic substances
on the gene expression proﬁles at the small RNA level in meat-
producing livestock, an animal trial was conducted to simulate
the real environment during a potential drug abuse situation. In
general, ultrahigh-throughput studies result in immensely huge
data output that is highly multivariate (k variables  n observa-
tions). To get the most value out of complex small RNA-Seq data
and reveal knowledge that is hiding behind, we implemented
multivariate projection methodologies to circumvent this bottle-
neck in biomarker development. The aim is to ﬁnd a valid and
stable biomarker signature, which explicitly leads back to the treat-
ment. Thereby, treated or diseased subjects will be compared with
untreated control samples. To select the most signiﬁcant single
biomarkers and combine this pattern to a biomarker signature,
the applicability of multivariate projection methodologies in omics
studies is beneﬁcial and productive [22]. Most applied multivariate
projection methodologies are principal-component analysis (PCA),
hierarchical clustering (HCA), and partial least-squares (PLS) pro-
jections to latent structures [22]. Recently, orthogonal partial least
squares (OPLS) demonstrated to be a useful discriminant anal-
ysis (DA) tool for complex data structures [23,24]. The goal of
OPLS-DA is to establish a model that is able to distinguish the
classes of observations (non-treated from treated), to visualize
large-volume data sets and to highlight meaningful interpretation
possibilities.
The OPLS algorithm [25] is an improved and complexity-
reduced interpretation of PLS regression models with an integrated
orthogonal correction ﬁlter [26], allowing easier interpretation and
augmenting classiﬁcation performance [27]. Therefore, systemic
variation from the input data set X, which is not correlating with
the response set Y, is eliminated [25]. High-quality OPLS-DA mod-
els have the ability to separate the modelled variation in X into
two parts, one that is correlated to Y and therefore predictive, and
another that is orthogonal to Y. Thus, the correlated and therefore
predictive variation in X is displayed by the predictive components
and represents the variation between classes (non-treated animals
and treatment groups). The variation in X that is orthogonal to Y is
modeled by the orthogonal components and reﬂects the variation
within classes [28].
Not only miRNAs but also piRNAs were investigated in this study
to evaluate the potential of both smexRNA biomarker candidates.
The decisive advantages of smexRNAs in bio-ﬂuids compared to
RNAs sampled from tissue are easy accessibility and an increased
stability in the body and after sample collection [29]. We  examine
and discuss the potential of smexRNAs as novel source of biomark-
ction and Quantiﬁcation 5 (2015) 15–22 17
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Fig. 1. Abundance of circulating miRNAs and piRNAs. Box plots illustrate the cir-
culating miRNA and piRNA proportions in plasma of untreated control animalsS. Melanie et al. / Biomolecular Dete
rs in veterinary diagnostics, to battle against illegal application of
rowth and performance enhancing substances to bovines.
. Material and methods
.1. Design of the animal study
In this study, 21 male Friesian Holstein veal calves (bos
aurus) were randomly divided into three groups of 7 ani-
als each (n = 7). All animals had a similar age (161 ± 15 days)
nd an average body weight of 151.4 ± 19.2 kg at the begin-
ing of the trial. One group remained completely untreated and
erved as control group (CON). The second group was treated
ith Component E–C (IVY Animal Health, USA), a hormonal
mplant that consisted of a combination of 100 mg  of proges-
erone plus 10 mg  of estradiol benzoate (steroid hormone group,
 + EB). One implant per animal was deposited between the
kin and the cartilage on the backside of the middle third of
he pinna of the ear. The third group received an oral dose
f clenbuterol-hydrochloride (clenbuterol group, CLEN) (10 g/kg
ody weight) (Boehringer Ingelheim, Germany) in daily intervals
or 36 days. This animal study was approved by the ethi-
al committee of the German Landesamt für Natur, Umwelt
nd Verbraucherschutz Nordrhein-Westfalen (permit number 84-
2.04.2012.A040). The animals were housed and fed according to
ood animal attendance practice and all efforts were made to pre-
ent suffering.
.2. Plasma sampling
To generate plasma, peripheral whole blood was collected from
he jugular vein using 9 ml  K3E K3EDTA-Vacuette tubes (Greiner
io-one, Germany) and single use needles (Greiner bio-one,
ermany) with a subsequent separation of cellular components by
entrifugation for 15 min  at 3500 × rcf at room temperature with
ransportable centrifuges (EBA20, Hettich, Germany). Plasma was
tored at −80 ◦C until RNA extraction. Samples were taken at d + 17
fter the initial treatments.
.3. Total RNA isolation
ExRNAs from plasma were isolated by an optimized method that
nabled small RNA-Seq as previously implemented by our group
30]. RNA eluates were stored at −80 ◦C until further usage.
.4. Small RNA Sequencing, Data Evaluation, Mapping and
nnotation
The sample pre-processing pipeline, analytical small RNA-Seq
teps on a HiSeq sequencing platform (Illumina, USA) and the
ioinformatics steps to generate annotated readcount tables of 21
ovine plasma samples were realized as described and discussed by
ur group [30]. As inter-sample normalization strategy, total read-
ounts were adjusted to library sizes in reads per million (rpm) to
orrect differences in library sizes [31].
.5. Univariate and multivariate data analysis
SigmaPlot 11.0 (Systat Software Inc., USA) was used for sta-
istical data analysis and SIMCA 13.0.3.0 software (Umetrics AB,
weden) for running the multivariate data analysis. For model
eneration, library size-normalized data sets were ﬁrst logarith-
ically transformed and then pareto-scaled [24]. Different miRNA
nd piRNA models, depending on the input data quantities, were
uilt. These were either readcount tables with all annotated reads(CON), steroid hormone- (P + EB) and clenbuterol (CLEN)-treated animals (n = 7
each). Steroid hormones decreased the miRNA quantity (p = 0.047) and clenbuterol
application resulted in increased miRNA concentrations (p = 0.042).
(all reads) or with more than 50 rpm at an average (>50 read-
counts). 50 rpm was set as a noise cut-off that is commonly used
in small RNA-Seq data analysis. Discriminative model results were
shown in scores scatter plots, displaying the CON group in blue,
the P + EB group in red and the CLEN group in green. The qual-
ity of OPLS-DA models was  controlled by evaluating R2 and Q2
values. The R2(cum) value represents the cumulative percentage
of the modelled variation in Y, using the X model. Therefore, the
R2(cum) value is the measure of ﬁt and describes how well the
model ﬁts the X data. A large value close to 1 is a requisite condition
for good models. The Q2(cum) value is the cumulative percentage
of the variation in Y that can be predicted by the model accord-
ing to cross validation using the X model. Q2(cum) is the measure
of predictability and explains how well the generated model pre-
dicts new data. A large value (>0.5) indicates good predictability
[28].
3. Results and discussion
3.1. Abundance of smexRNAs
After passing the sequencing quality checkpoints and successful
alignment, miRNA and piRNA data from all sequenced 21 animals
were library-size normalized and compiled in readcount tables.
Analysis of the proportion of miRNAs on the total sequenced
reads resulted in a content of 5.7% ± 2.4 (SD) (median = 6.6) in the
CON group, 3.5% ± 1.7 (SD) (median = 3.6) in the P ± EB group and
6.6% ± 2.7 (SD) (median = 7.9) in the CLEN group (Fig. 1). There is a
statistically signiﬁcant difference between the CON group and the
steroid hormone treated group (p = 0.047) and also between the two
treatment groups (p = 0.042). Concerning piRNAs, CON contained
0.7% ± 0.4 (SD) (median = 0.6), P ± EB 1.0% ± 0.7 (SD) (median = 0.8)
and CLEN 1.1% ± 1.0 (SD) (median = 0.6) without statistically signif-
icant differences (Fig. 1).
As the magnitude of piRNAs was  comparable to previously pub-
lished data of nine healthy bovines [32], the proportion of piRNAs
seemed not to alter even under the inﬂuence of anabolic stimulants.
It was a recognizable effect that the steroid treatment led to a sig-
niﬁcant decrease of miRNA quantity compared to the CON  group. In
the CLEN-treated animals, gene expression changes towards an up-
regulation of miRNAs were noticed compared to the P + EB treated
18 S. Melanie et al. / Biomolecular Detection and Quantiﬁcation 5 (2015) 15–22
Table 1
Comparison of the top 10 expressed miRNAs and piRNAs in the three analyzed groups: (CON) control group, (P + EB) steroid hormone-treated group, (CLEN) clenbuterol-
treated  group. Checkmarks signify presence of matching small RNAs and superscript numbers give ranking information. Pie charts depict the percentage of the top 10 on the
total  annotated miRNAs and piRNAs, respectively.
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nndividuals. Therefore, the different kinds of treatment substances
eemed to have an opposite impact on miRNA translation.
.2. Top 10 abundance lists
Rpm-normalized miRNA reads were sorted according to their
ecreasing readcount numbers to generate top 10 abundance lists.
his revealed that the largest proportion of the data sets was
eﬂected by the top 10 ranks: 84.2% in the CON group, 76.0% in
he P + EB group and 83.8% in the CLEN group (Table 1). By com-
aring the most abundant CON miRNAs with the P + EB and CLEN
reatment group, it could be stated that the composition is nearly
he same (CON vs. P + EB) or exactly matching (CON vs. CLEN). The
op 10 signature of the CON group conﬁrmed miR-3600, which
as substituted with miR-140 in the P + EB group. To evaluate piR-
As that were high ranking in terms of abundance, the same data
rganization was conducted. The top 10 piRNA list accounted for
1.3% of the total reads data set in the CON group, for 82.2% in
he P + EB group and for 92.3% in the CLEN group. The CON and
LEN piRNA list exhibited the same pattern and the P + EB group
aried in three piRNAs: piR-31038, piR-35284 and piR-33082. A
tatistically signiﬁcant difference between the groups could not be
etected. Therefore, in summary for both treatment groups, the
eadcount data sets were highly affected by the most abundant
iRNA and piRNA proﬁles. Moreover, top 10 expressed data did
ot show signiﬁcant deviations from the CON group, indicatingthat the smexRNA proﬁles of treated animals were not subject of
ﬂuctuations as great as assumed and the major components were
constantly expressed.
3.3. Differential expression
To evaluate the discriminative power of multivariate data analy-
ses to identify animals after veterinary drug application on the basis
of smexRNAs, OPLS-DA was performed after data pre-processing.
miRNA and piRNA scores scatter plots were analyzed regarding
between class variation (horizontal direction) and within class vari-
ation (vertical direction) depending on the read input of either all
aligned reads (all reads) or size-ﬁltered data sets with reads that
had averagely more than 50 rpm (>50 readcounts) (Figs. 2–4), ,
). Fig. 5 gives an overview over model quality parameters of all
examined discriminative analyses.
First, the discriminative power of combined data sets includ-
ing miRNAs and piRNAs was examined. As shown in Fig. 2[A]
and [B], the separation between the CON animals and the treated
groups, based on miRNA observations >50 readcounts, is imper-
fect. Although moderate goodness of ﬁt and prediction could
be attested for the CLEN study model (CLEN: R2(cum) = 0.752,
Q2(cum) = 0.458), it was not feasible for the P + EB study (P + EB:
R2(cum) = 0.319, Q2(cum) = 0.001). Better discriminative and qual-
ity results were accomplished with models that included all reads
(Fig. 2[C] and [D]). DA could not manage to perfectly separate the
S. Melanie et al. / Biomolecular Detection and Quantiﬁcation 5 (2015) 15–22 19
Fig. 2. Combined miRNA and piRNA data set.  OPLS-DA of sequenced plasma samples using full [C and D] and readcount-ﬁltered datasets [A and B]. [A and C] represent
scores scatter plots discriminating control animals (CON, blue) from steroid hormone-treated animals (P + EB, red). [B] and [D] display samples from the CON and the
clenbuterol-treated population (CLEN, green). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version of this article.)
Fig. 3. MiRNA data set. OPLS-DA of sequenced plasma samples using full [C and D] and readcount-ﬁltered datasets [A and B]. [A and C] represent scores scatter plots
discriminating control animals (CON, blue) from steroid hormone-treated animals (P + EB, red). [B] and [D] display samples from the CON and the clenbuterol-treated
population (CLEN, green).
Fig. 4. PiRNA data set. OPLS-DA of sequenced plasma samples using full [C and D] and readcount-ﬁltered datasets [A and B]. [A and C] represent scores scatter plots
discriminating control animals (CON, blue) from steroid hormone-treated animals (P + EB, red). [B] and [D] display samples from the CON and the clenbuterol-treated
population (CLEN, green).
20 S. Melanie et al. / Biomolecular Detection and Quantiﬁcation 5 (2015) 15–22
Fig. 5. Model quality overview. The R2(cum) value (dark colored bars) reﬂects the goodness of ﬁt and the Q2(cum) value (light colored bars) the goodness of prediction.
Quality parameters were evaluated for the data set with all reads and with reads over averagely more than 50 readcounts (>50 readcounts). Red colored bars display the
values  from the P + EB study and green colored bars the values from the CLEN study.
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QLEN-treated animals from the CON group (CLEN: R2(cum) = 0.794;
2(cum) = 0.355), while acceptance of all reads in the discrimina-
ive analysis led to a model that allowed separation of P + EB classes
ith high quality (P + EB: R2(cum) = 924, Q2(cum) = 0.657).
In a second step, to examine a potentially improved discrim-
native power of data sets with uniquely miRNAs or piRNAs
espectively, equivalent OPLS-DA models were generated. As
hown in Fig. 3[A] and [B], the separation between the CON animals
nd the treated groups, based on miRNA observations >50 read-
ounts, is not more speciﬁc. The model quality parameters attest
etter ﬁt and prediction for the CLEN study (CLEN: R2(cum) = 0.607,
2(cum) = 0.377; P + EB: R2(cum) = 0.210, Q2(cum) = 0.035) but
till, best discriminative and quality results were accomplished
ith models that included all available reads. For both multivariate
ata analyses studies, the miRNA models were able to distinguish
etween classes (Fig. 3[C] and [D]), which was reﬂected by good ﬁt
CLEN: R2(cum) = 0.927; P + EB: R2(cum) = 0.893) as well as good
redictability (CLEN: Q2(cum) = 0.782; P + EB: Q2(cum) = 0.706).
enerally, large R2 and Q2 values at the level of 0.5 or above are
ecessary for high quality OPLS-DA models. Therefore, the qual-
ty parameters of the miRNA OPLS-DA models for the P + EB and
he CLEN-treated animals indicated that the models ﬁtted the data
ery well and that new variables could be predicted. Using all reads,
he scores scatter plots illustrated a grouping of the CON and the
reated animals, highlighting that multivariate data analysis tools
ere clearly capable to reveal treatment-dependent differences at
he miRNA level. Moreover, fusion of data sets did not deliver bet-
er ﬁtting and predicting results compared to miRNAs only, neither
or the different treatment groups nor for the two  compared data
nputs.
Besides miRNAs, OPLS-DA models were generated and evalu-
ted for piRNA data only (Fig. 4). Here again, a separation of the
reatment groups was not feasible for the data set >50 readcounts.
ccording to that effect, R2 and Q2 could not meet quality standards
CLEN: R2(cum) = 0.221, Q2(cum) = 0.055; P + EB: R2(cum) = 0.536,
2(cum) = 0.096). Compared to the miRNA models, the piRNA mod-
ls with all reads could not cluster the treated animals. For the
 + EB group, a better OPLS-DA model could be generated than
or the CLEN group, also regarding quality (CLEN: R2(cum) = 0.461,
2(cum) = −0.346; P + EB: R2(cum) = 0.706, Q2(cum) = 0.47). TheDA of piRNAs could not present acceptable models, as they could
not explain the variation of the variables nor could they predict.
Obviously, the miRNA abundance and thus the utilizable read num-
bers for statistical analyses exceed that of piRNAs (Fig. 1). Therefore,
miRNA OPLS-DA could be based on increased data volumes sup-
porting a better prediction ability and discrimination. Fusion of data
sets delivered better ﬁtting and predicting results compared to piR-
NAs only, when using all reads. For the CLEN study, the combined
model also presented better ﬁt and prediction for the >50 read-
count model. For the miRNAs from the P + EB study, merging data
sets resulted in slightly increased R2 values using all reads. Best
ﬁt and prediction in the CLEN study were achieved while using all
miRNA reads (Fig. 3[D]). In summary, adding miRNAs to improve a
piRNA based model resulted in better discrimination, ﬁt and pre-
dictability, whereas miRNAs alone (all reads) provided best results
for both treatment modalities. Referring to this trial, it can be con-
cluded that DA is improving the more data (reads) are fed into
OPLS-DA. It became apparent that OPLS-DA is best suited for full
datasets of circulating miRNAs in the search for veterinary drug
abuse biomarkers.
3.4. Comparison of analysis models
Taking all ﬁndings together, it can be stated that the main per-
centage of the miRNA and piRNA signature is composed of the
top 10 candidates (Table 1). Furthermore, the miRNA and piRNA
top 10 signature is almost the same, if the CON group was com-
pared with the P + EB animals, or even identical (CON vs. CLEN).
No statistically signiﬁcant expression ratio could be determined.
Therefore, the investigated smexRNAs were expressed more stable
than assumed. It was though already published that the treatments
were effective, as animals showed a signiﬁcant weight gain (d0 to
d + 34) and a potential gene expression biomarker signature was
identiﬁed on the mRNA level in liver samples in the course of
the same animal trial [21]. Nevertheless, overall variation in the
expressed miRNA proﬁles is sufﬁcient for the generation of good-
quality OPLS-DA models, but this variation was  not explained by the
main components of the data set, but rather by the multiplicity of
low-abundance miRNAs. Increasing the sequencing depth to exem-
plary 24-fold (one sample per ﬂow cell lane) could thereby help to
ction 
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mprove the detection of low-abundant smexRNAs, the sequencing
f more reads and ﬁnally the manifestation of differences in low-
bundance circulating small RNAs. As explained before, there is a
iscriminative effect lying in the data, however hiding behind the
ajor expressed circulating miRNAs.
The quality of miRNA models (all reads) for both treatment
roups is predominant to those generated with combined data sets
r piRNAs alone. Therefore, the presented results highlighted that
iRNAs were superior biomarker candidates to piRNAs regard-
ng the annotated number of reads, model quality, data ﬁt and
redictive ability. Therefore, based on the presented compara-
ive OPLS-DA data analyses, miRNAs are the favorable smexRNA
iomarker candidates in the research ﬁeld of veterinary drug abuse.
s treated animals could be separated from untreated controls,
his study was a ﬁrst hint, that circulating miRNAs could be ben-
ﬁcial biomarker candidates for anabolic misuse in the future, if
equencing depth is chosen properly.
Although there were clear differences between the control and
he treated animals revealed by small RNA-Seq (scores scatter
lots in Figs. 2 and 3), the veriﬁcation and validation of a conﬁ-
ent biomarker signature is technically very difﬁcult for smexRNAs
n bovine plasma. To experimentally manifest the quantitative
xpression of candidates in plasma via RT-qPCR, a detectable read-
ount number is prerequisite. As described before, those miRNAs
hat fulﬁlled this precondition were stably expressed and did not
nderlie variation that is owed to the anabolic treatments. There-
ore, due to a very low concentration of smexRNAs in bovine
lasma, a sufﬁcient sample volume, an efﬁcient RNA isolation
ethod and appropriate sequencing strategies need to be united
or successful screening and validation experiments.
In summary, smexRNAs could be seen as potential candidates in
he identiﬁcation of biomarkers with the ability to uncover illegal
rug application in veterinary diagnostics. Using multivariate pro-
ection methodologies like OPLS-DA have proven the best potential
o generate discriminative miRNA models, supported by small RNA-
eq data. PiRNAs were expressed with low copy numbers, which
s not ensuring statistical robustness and signiﬁcance. OPLS-DA
nabled insights into the complex structure of sequencing data
nd clariﬁed that value could be gained from the presented exper-
ments, namely information about differentiation of treatment
roups. However, the quantitative analysis in plasma is challeng-
ng as the content of miRNAs or piRNAs seemed robust in bovine
lasma (Fig. 1, [32]) and differences in the abundance of minor
xpressed smexRNAs could not be revealed. Therefore, the assumed
odiﬁcations of the smexRNA proﬁle by growth-promoting sub-
tances was overestimated. Yet, it must not be forgotten that blood
nd hence plasma underlie extreme systemic inﬂuences. The blood-
tream is permanently in direct contact with the complete organ
ystem. Hence, the circulating small RNA proﬁle could be heav-
ly altered only throughout one circulation through the body. As
escribed before, steroidal hormone implants as well as the oral
lenbuterol doses were effective, but it might be the case that
he potential alterations in the small RNA signatures could not be
aptured due to rapid turnover of the circulation system. To the
resent date, it could not be described in literature, that smexR-
As are the direct targets of stimulants like steroid hormones or
-2-adrenergic agonist. Therefore, for transcriptional biomarker
evelopment, a long-term and permanent miRNA pattern needs
o be detected, which is not inﬂuenced by the animal circulatory
ystem.. Conclusion
In transcriptional biomarker discovery, easy collectable sample
pecimen like whole blood, serum or plasma offer advantages in
[
[
[and Quantiﬁcation 5 (2015) 15–22 21
veterinary routine diagnostics but meet methodological difﬁcul-
ties, mainly due to matrix complexity, low RNA concentration and
bioinformatical challenges. As miRNAs in plasma were tested to
be highly stable and resistant to degradation [29], smexRNAs are
seen as very potential candidates in the search for the next gener-
ation of transcriptional biomarkers. The presented experimental
pipeline offered to analyze circulating miRNAs and piRNAs in
bovines under anabolic stimulation. The usability of small RNA-Seq
in the search for novel miRNA biomarkers in veterinary medicine
was demonstrated here, as OPLS-DA discriminative models could
be successfully created that also showed high goodness of ﬁt and
predictability. Next steps in the experimental lineup would be
to deeper sequence plasma samples in order to provide detailed
information about the composition of the smexRNA proﬁle at low-
abundance levels. Furthermore, RNA isolation systems from bio
ﬂuids still need enhanced performances to extract sufﬁcient con-
centrations of smexRNAs that can be measured with RT-qPCR.
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